The European Genomic Data Infrastructure (GDI) allows researchers to access European genomic and clinical data. The aim is to improve diagnostics and pharmacogenomics – in other words, to improve the impact of individual differences in hereditary factors on drug response. Another aim is to support the secondary use of these data for research. Valuable data will been collected from patients with cancers and rare and polygenic diseases. Data has also been collected on disease-causing pathogens as well as infectious diseases such as COVID-19.
CSC as co-leads of the infrastructure pillar has a leading role in this work. Also the Life Science AAI (Authentication and Authorization Infrastructure) & REMS (Resource Entitlement Management System) are applications already in use to support access management to data. The Starter Kit has been created for the basis of GDI. The Starter Kit includes more than 2,500 synthetic genomics and phenotypic data on cancer and rare diseases. It is a first step towards a production infrastructure.
Read more here:
ELIXIR is partly funded by the European Commission